The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

MCC vaccination has had important consequences for meningococcal population biology, and carriage studies were essential in measuring these effects. The potential for herd immunity should be taken ...

Preliminary results from a phase 3 study of the MenABCWY vaccine – which covers all five meningococcal strains in one go as an alternative to separate vaccinations – showed that it was at ...

Feb. 5, 2025 — Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful ...